Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Assembly Biosciences, Inc.    ASMB

ASSEMBLY BIOSCIENCES, INC.

(ASMB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
6.22(c) 6.13(c) 6.115(c) 6.16(c) 6.06 Last
1 081 758 614 123 819 530 1 170 743 568 315 Volume
+2.47% -1.45% -0.24% +0.74% -1.62% Change
More quotes
Financials (USD)
Sales 2020 82,0 M - -
Net income 2020 -53,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,96x
Yield 2020 -
Sales 2021 14,0 M - -
Net income 2021 -124 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,75x
Yield 2021 -
Capitalization 203 M 203 M -
Capi. / Sales 2020 2,48x
Capi. / Sales 2021 14,5x
Nbr of Employees 140
Free-Float 88,6%
More Financials
Company
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules... 
More about the company
Notations Surperformance© of Assembly Biosciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ASSEMBLY BIOSCIENCES, INC.
2020ASSEMBLY BIOSCIENCES : Jefferies Adjusts Price Target for Assembly Biosciences t..
MT
2020Assembly Biosciences To End Microbiome Program, Focuses on Hepatitis B Virus ..
MT
2020ASSEMBLY BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, ..
AQ
2020Assembly Biosciences to Wind-Down Microbiome Program
GL
2020Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635..
GL
2020Mizuho Adjusts Assembly Biosciences' PT to $13 From $30 After H0731 'Failure ..
MT
2020ASSEMBLY BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
2020ASSEMBLY BIOSCIENCES : Appoints Nicole S. White, PhD, as Senior Vice President o..
AQ
2020Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President ..
GL
2020Assembly Biosciences, Door Pharmaceuticals Team Up On Developing HBV Core Pro..
MT
2020ASSEMBLY BIOSCIENCES : and Door Pharmaceuticals Sign Collaboration and Option Ag..
AQ
2020Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option A..
GL
2020Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster..
GL
2020ASSEMBLY BIOSCIENCES : Presents Data from HBV Core Inhibitor Programs in Poster ..
AQ
2020ASSEMBLY BIOSCIENCES : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c..
AQ
More news
News in other languages on ASSEMBLY BIOSCIENCES, INC.

- No features available -

More news
Analyst Recommendations on ASSEMBLY BIOSCIENCES, INC.
More recommendations
Chart ASSEMBLY BIOSCIENCES, INC.
Duration : Period :
Assembly Biosciences, Inc. Technical Analysis Chart | ASMB | US0453961080 | MarketScreener
Technical analysis trends ASSEMBLY BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 18,60 $
Last Close Price 6,16 $
Spread / Highest target 631%
Spread / Average Target 202%
Spread / Lowest Target 13,6%
EPS Revisions
Managers and Directors
NameTitle
John G. McHutchison President, Chief Executive Officer & Director
William R. Ringo Independent Non-Executive Chairman
Thomas J. Russo Chief Financial & Accounting Officer
Steven J. Knox Senior Vice President-Clinical Development
Luisa M. Stamm Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ASSEMBLY BIOSCIENCES, INC.1.82%203
MERCK KGAA1.67%75 058
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.39%27 359
KYOWA KIRIN CO., LTD.0.43%14 729
BETTA PHARMACEUTICALS CO., LTD.28.34%8 355
YUHAN CORPORATION-2.53%4 163